Aspirin in the primary prevention of coronary disease. Is it good for everybody?
Lama, A.; Vega, Ján.
Revista Medica de Chile 132(7): 886-888
2004
ISSN/ISBN: 0034-9887 PMID: 15379339 Document Number: 570248
Document emailed within 1 workday
Related Documents
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25Miser, W.Fred. 2011: Appropriate aspirin use for primary prevention of cardiovascular disease American Family Physician 83(12): 1380-1386
Lindbloom, E.J.; Eaton, L.J. 2002: Cost effectiveness of aspirin vs clopidogrel for secondary prevention of coronary heart disease Journal of Family Practice 51(9): 789
De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Young, F.E.; Nightingale, S.L.; Temple, R.A. 1988: The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction JAMA 259(21): 3158-3160
Pignone, M.; Mulrow, C. 2002: Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease Bmj 324(7342): 917
Piwoński, J.; Rywik, S. 1981: Opinion of the Polish scientific community concerning selected problems in the prevention of coronary disease. I. The theoretical premises of primary prevention Kardiologia Polska 24(11-12): 789-797
Novák, J. 1988: The program for primary prevention and secondary prevention of ischemic coronary disease and research at the Laboratory of Human Energy Resources of the University of Wyoming in Laramie Casopis Lekaru Ceskych 127(37-38): 1190-1192
1980: Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group Circulation 62(3): 449-461
Stamler, J. 1973: Heart disease prevention in industry. Primary prevention in mass community efforts to control the major coronary risk factors: the challenges and possibilities--critical issues and outlook for the future Journal of Occupational Medicine.: Official Publication of the Industrial Medical Association 15(1): 54-59
Kannel, W.B. 1990: Implications of the primary prevention trials against coronary heart disease Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 8(7): S245-S250
Gliksman, M.D.; Dwyer, T.; Boulton, T.J. 1987: Should the primary prevention of coronary heart disease commence in childhood? Medical Journal of Australia 146(7): 360-362
Meinertz, T.; Heitzer, T. 2002: Primary and secondary prevention of coronary heart disease: smoking Zeitschrift für Kardiologie 91 Suppl. 2: 3-11
Wicklmayr, M.; Rett, K.; Standl, E. 1994: How can primary prevention of coronary heart disease be improved in general practice? Medizinische Klinik 89(4): 184-6 229
Wilhelmsen, L. 1977: Primary and secondary risk factors for coronary heart disease: their role in prevention Medical Journal of Malaysia 31(4): 296-301
Carneiro, Aónio.Vaz.; Costa, Jão.; Borges, M. 2004: Statins for primary and secondary prevention of coronary heart disease. A scientific review Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 23(1): 95-122
Burrill, P.D. 2010: Aspirin in primary prevention. Evidence is lacking Bmj 340: C1613
Agustí, Aònia.; Diogène, E. 2004: Primary prevention of acute myocardial infarction with aspirin Medicina Clinica 122(15): 592-594
Grundy, S.M. 1992: Primary prevention of coronary heart disease with drug therapy. Safety and total mortality issues Archives of Internal Medicine 152(7): 1369-1371
Rakická, E.; Stolz, I.; Geizerová, H.; Widimský, J.; Matousová, M.; Hejl, Z.; Hurych, J.; Petrzilková, Z.; Pistulková, H.; Kaucká, J. 1982: Obstacles and possibilities of influencing physical activity within the framework of primary prevention of ischemic coronary disease Vnitrni Lekarstvi 28(11): 1102-1108